Breathe Well Live Well
Conditions: Asthma; Elevated Blood Eosinophils
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified July 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Vitamin D improves corticosteroid efficacy and attenuates its side-effects in an animal model of asthma.
Can J Physiol Pharmacol. 2014 Nov 3;:1-9
Authors: Mehta AA, Agrawal AD, Appanna V, Chaudagar KK
Abstract
The subacute use of corticosteroids has side-effects such as glucose intolerance, dyslipidemia, anxiety, and depression, which could be halted with vitamin D, which is an immunomodulatory vitamin. Thus, we aimed to study the anti-asthmatic efficacy and side-effects profile of vitamin D, the corticosteroid dexamethasone, and their combination on ovalbumin-induced airway inflammation in rats. For this, 2 different doses of vitamin D (50 IU/kg, daily for 2 weeks, or and 60000 IU/kg, bolus dose, by intraperitoneal injection (i.p.)) were administered in combination with dexamethasone (2.5 mg/kg, i.p., for 2 weeks) prior to challenge with ovalbumin. At the end of the therapy, the asthmatic parameters such as differential white blood cell counts, serum levels of immunoglobulin E, bronchoalveolar lavaged fluid, and interleukin-5, as well as serum levels of nitric oxide were significantly increased after allergen challenges in asthmatic rats as compared with the controls. Such increases were significantly attenuated by monotherapy with vitamin D and with combination therapy of vitamin D and dexamethasone, where the combination therapy was superior to the monotherapy. Dexamethasone-induced hyperglycemia, hyperlipidemia, and behavioral abnormalities in the allergic rats were attenuated with vitamin D. The daily dose was better for controlling serum levels of immunoglobulin E than the bolus dose, whereas the bolus was superior for reducing dexamethasone-induced psychotropic abnormalities. There were no significant changes in other parameters between the daily and the bolus dose. In conclusion, a daily dose of vitamin D in combination with dexamethasone is more efficacious for treating asthma in allergic rats than monotherapy.
PMID: 25429688 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Oral Corticosteroid Dependent Asthma
Interventions: Biological: Tralokinumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Guardian Liberty Voice |
Corticosteroid Asthma Inhalers May Suppress Growth in Children
Guardian Liberty Voice asthma Hundreds of thousands of children with asthma use corticosteroid inhalers to help them breathe, but according to a new study from Brazil the medications commonly found in those inhalers may suppress growth. The scientific review, which … |
View full post on asthma – Google News
Science 2.0 |
Corticosteroid Drugs Used For Asthma Suppress Growth – Systematic Reviews
Science 2.0 They are the most effective drugs for controlling asthma and clearly reduce asthma deaths, hospital visits and the number and severity of exacerbations, and improve quality of life. Worldwide, seven ICS drugs are currently available: beclomethasone, … |
View full post on asthma – Google News
|
Initiation of Inhaled Corticosteroid and Long-Acting b2-adrenergic Agonist …
AJMC.com Managed Markets Network Study Design: The current study is a retrospective cohort analysis of patients with asthma, aged 12 to 64 years, new to ICS/LABA combination therapy, using—US healthcare claims data between June 1, 2007, and December 31, 2010. Methods: Patients with … |
View full post on asthma – Google News
Condition: Asthma
Intervention: Drug: Oral Corticosteroids
Sponsors: St. Justine’s Hospital; Canadian Institutes of Health Research (CIHR)
Recruiting – verified December 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
| Related Articles |
Restoration of Corticosteroid Sensitivity by p38 Mitogen Activated Protein Kinase Inhibition in Peripheral Blood Mononuclear Cells from Severe Asthma.
PLoS One. 2012;7(7):e41582
Authors: Mercado N, Hakim A, Kobayashi Y, Meah S, Usmani OS, Chung KF, Barnes PJ, Ito K
Abstract
BACKGROUND: Severe asthma accounts for a small number of asthmatics but represents a disproportionate cost to health care systems. The underlying mechanism in severe asthma remains unknown but several mechanisms are likely to be involved because of a very heterogeneous profile. We investigated the effects of a p38MAPK inhibitor in corticosteroid sensitivity in peripheral blood mononuclear cells (PBMCs) from severe asthmatics and the profile of its responders.
METHODOLOGY/PRINCIPAL FINDINGS: Corticosteroid sensitivity was determined by measuring dexamethasone inhibition of CD3/28 and TNF-? induced IL-8 production in PBMCs by using ELISA. PBMCs from severe asthmatics were relatively less sensitive to dexamethasone (Dex) as compared to those of non-severe asthmatics and healthy volunteers. The IC(50) values of Dex negatively correlated with decreased glucocorticoid receptor (GR) nuclear translocation assessed using immunocytochemistry (r?=?-0.65; p<0.0005) and with decreased FEV(1) (% predicted) (r?=?0.6; p<0.0005). A p38?/? inhibitor (SB203580) restored Dex-sensitivity in a subpopulation of severe asthma that was characterized by a defective GR nuclear translocation, clinically by lower FEV(1) and higher use of oral prednisolone. We also found that SB203580 partially inhibited GR phosphorylation at serine 226, resulting in increased GR nuclear translocation in IL-2/IL-4 treated corticosteroid insensitive U937s.
CONCLUSIONS/SIGNIFICANCE: p38MAPK?/? is involved in defective GR nuclear translocation due to phosphorylation at Ser226 and this will be a useful biomarker to identify responders to p38MAPK?/? inhibitor in the future.
PMID: 22911818 [PubMed – in process]
View full post on pubmed: asthma
 Hispanically Speaking News (blog) |
Obese children with asthma need higher corticosteroid doses
Clinical Advisor HealthDay News — Overweight and obese children with asthma do not respond as well to corticosteroids as normal weight children and require higher daily doses of the medication, study data presented at the annual meeting of the American Academy of … AAAAI: Corticosteroid Response in Asthma Impacted by BMI Heavy Kids May Not Respond as Well to Asthma Meds |
View full post on asthma – Google News
|
AAAAI: Corticosteroid Response in Asthma Impacted by BMI
Doctors Lounge For children with asthma, an increased body mass index is associated with a decreased response to corticosteroids and increased daily requirements for inhaled corticosteroids, according to a study presented at the annual meeting of the American Academy … |
View full post on asthma – Google News